Back to News
Market Impact: 0.22
AIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares Jump
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & BiotechCompany Fundamentals
AIM ImmunoTech secured European and U.K. patent protection for Ampligen (rintatolimod) for Long COVID, with exclusivity expected to run through June 2041. The development strengthens IP durability for its Long COVID program and should be supportive of longer-term commercial optionality.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AIM0.65
More News
- McDonald's is hosting an investor day as its U.S. business struggles. Here are 4 things to expect
- Nscale’s IPO will test Wall Street’s appetite for concentrated AI bets once again
- OpenAI punted. Anthropic stalled. The hottest imminent IPO fits on your finger
- Peloton is revamping its treadmills with new features in the next phase of its turnaround
- Nvidia’s Stock Is Flashing a Warning Sign as Valuation Falls
- Sandisk has gained more than 600% in 2026. It still has room to run, Rosenblatt says
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search